ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box with 1 vial

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Curacef Duo, 50 mg/ml / 150 mg/ml Suspension for injection for cattle
Ceftiofur
Ketoprofen

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Ceftiofur (as hydrochloride)	50.0 mg/ml
Ketoprofen	150.0 mg/ml

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

1 x 50 ml
1 x 100 ml
1 x 250 ml

5. TARGET SPECIES

Cattle

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake the bottle vigorously for 20 seconds before use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Meat and offal: 8 days. Milk: zero hours.

9. SPECIAL WARNING(S), IF NECESSARY

Penicillins and Cephalosporins (including Ceftiofur) or Ketoprofen may occasionally cause severe allergic reactions.
Read the package leaflet before use.

10. EXPIRY DATE

EXP: {month/year}
Once opened, use within 28 days.
Once broached, use by:

11. SPECIAL STORAGE CONDITIONS

Do not freeze.
For the glass vial only : Keep the glass vial in the outer carton in order to protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Virbac
1ère avenue - 2065m – L.I.D.
06516 Carros Cedex
France

16. MARKETING AUTHORISATION NUMBER

Vm 05653/4178

17. MANUFACTURER'S BATCH NUMBER

Batch : {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Glass or plastic vial of 50 or 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Curacef Duo, 50 mg/ml / 150 mg/ml Suspension for injection for cattle
Ceftiofur
Ketoprofen

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Ceftiofur (as hydrochloride)	50.0 mg/ml
Ketoprofen	150.0 mg/ml

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

50 ml
100 ml

4. ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake the bottle vigorously for 20 seconds before use.

5. WITHDRAWAL PERIOD

Meat and offal: 8 days. Milk: zero hours.

6. BATCH NUMBER

Batch : {number}

7. EXPIRY DATE

EXP : {month/year}
Once broached, use by:

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Glass or plastic vials of 250 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Curacef Duo, 50 mg/ml / 150 mg/ml Suspension for injection for cattle
Ceftiofur
Ketoprofen

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Ceftiofur (as hydrochloride)	50.0 mg/ml
Ketoprofen	150.0 mg/ml

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

250 ml

5. TARGET SPECIES

Cattle

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake the bottle vigorously for 20 seconds before use.

8. WITHDRAWAL PERIOD

Meat and offal: 8 days. Milk: zero hours.

9. SPECIAL WARNING(S), IF NECESSARY

Penicillins and Cephalosporins may occasionally cause severe allergic reactions.
Read the package leaflet before use.

10. EXPIRY DATE

EXP: {month/year}
Once broached, use by:

11. SPECIAL STORAGE CONDITIONS

Do not freeze.
For the glass vial only: Keep the glass vial in the outer carton in order to protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Virbac
1ère avenue - 2065m – L.I.D.
06516 Carros Cedex
France

16. MARKETING AUTHORISATION NUMBER

Vm 05653/4178

17. MANUFACTURER'S BATCH NUMBER

Batch: {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:

CURACEF DUO, 50 mg/ml / 150 mg/ml Suspension for injection for cattle

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:
Virbac
1ère avenue - 2065m – L.I.D.
06516 Carros Cedex
France

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

CURACEF DUO, 50 mg/ml / 150 mg/ml Suspension for injection for cattle

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:
Active substances:

Ceftiofur (as hydrochloride)	50.0 mg
Ketoprofen	150.0 mg

Off - white to pinkish suspension

4. INDICATION(S)

For the treatment of bovine respiratory disease (BRD) caused by *Mannheimia haemolytica* and *Pasteurella multocida* susceptible to ceftiofur and the reduction of associated clinical signs of inflammation or pyrexia.

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to ceftiofur and other β-lactam antibiotics.
Do not use in cases of hypersensitivity to ketoprofen.
Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans.
Do not use in cases of known resistance to other cephalosporins or beta-lactam antibiotics.
Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia.

6. ADVERSE REACTIONS

In field studies, the product has been tested in cattle aged from 1 month old to 12 years without evidencing safety concern.

Mild inflammatory reactions at the injection site, such as tissue oedema, without pain in most cases, were commonly observed in studies.

Hypersensitivity reactions (e.g. skin reactions, anaphylaxia) unrelated to dose and discolouration of the subcutaneous tissue and/or muscle can very rarely be observed.

Gastric or renal intolerance can be observed very rarely in certain individuals, in common with all NSAIDs due to their action of inhibition of prostaglandin synthesis.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Alternatively you can report via your national reporting system.

7. TARGET SPECIES

Cattle

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Intramuscular use

1 mg ceftiofur /kg /day and 3 mg ketoprofen /kg /day by intramuscular injection, i.e. 1 ml/50 kg at each injection. The product should only be used when the disease is associated with clinical signs of inflammation or pyrexia. The product may be administered for 1 to 5 consecutive days depending upon the clinical response on a case by case basis. As the duration for the antibiotic treatment should not be less than 3 to 5 days, when inflammation and pyrexia have subsided, the veterinarian should switch to a ceftiofur only-containing product in order to cover 3 to 5 days of continuous antibiotic treatment. Only few animals are expected to require a fourth or fifth injection with the combined product.

9. ADVICE ON CORRECT ADMINISTRATION

Shake the bottle vigorously for 20 seconds before use to ensure an homogeneous suspension.
Resuspension could be longer after storage at low temperatures.

To ensure correct dosage body weight should be determined as accurately as possible to avoid underdosing.
The user should use the most appropriate vial size according to the number of animals to treat. 50 ml and 100 ml vials should not be pierced more than 10 times and the 250 ml not more than 18 times. The use of an aspirating needle may be recommended to avoid excessive broaching of the stopper
Subsequent intramuscular injections must be given at different sites.
Not more than 16 ml should be administered per injection site.

10. WITHDRAWAL PERIOD

Meat and offal: 8 days.
Milk: zero hours.

11. SPECIAL STORAGE PRECAUTIONS

Do not freeze.
Keep the glass vial in the outer carton in order to protect from light.
Keep out of the sight and reach of children.

Do not use this veterinary medicinal product after the expiry date which is stated on the label or carton after “EXP”.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.

Special precautions for use in animals:
In case of the occurrence of allergic reaction the treatment should be withdrawn.

The product selects for resistant strains such as bacteria carrying extended spectrum betalactamases (ESBL) and may constitute a risk to human health if these strains disseminate to humans e.g. via food. For this reason, the product should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly (refers to very acute cases when treatment must be initiated without bacteriological diagnosis) to first line treatment.
When inflammation or pyrexia have subsided, the veterinarian should switch to a ceftiofur only-containing product in order to cover 3 to 5 days of continuous antibiotic treatment. Treating for an appropriate length of time is important to limit development of resistance.
Official, national and regional antimicrobial policies should be taken into account when the product is used. Increased use, including use of the product deviating from the instructions given in the SPC, may increase the prevalence of such resistance. Whenever possible, the product should only be used based on susceptibility testing.
The product is intended for treatment of individual animals. Do not use for disease prevention or as a part of heard health programmes. Treatment of groups of animals should be strictly restricted to ongoing disease outbreaks according to the approved conditions of use.

The concomitant use of diuretics or coagulant should be based on a benefit/risk assessment of the responsible veterinarian.

Avoid intra-arterial and intravenous injection.
Use preferably a 14 gauge needle.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Ketoprofen may also cause hypersensitivity. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised to active substances or to any of the ingredients, or if you have been advised not to work with such preparations.
Wash hands after use.
Avoid contact with eyes and skin. In case of contact, wash immediately with water.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning.
Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.
In case of accidental self injection seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:
Even though studies in laboratory animals with ceftiofur or ketoprofen show no evidence of teratogenesis, abortion or influence on reproduction, the reproductive safety of the product has not been specifically investigated in pregnant cows.
Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Do not use in combination with other NSAIDs or with corticosteroids, diuretics, nephrotoxic drugs or anticoagulants.
The bactericidal properties of beta-lactams are neutralised by simultaneous use of bacteriostatic antibiotics (macrolides, sulphonamides and tetracyclines).

Overdose (symptoms, emergency procedures, antidotes):
No signs of systemic toxicity of the product have been observed at doses up to 5 times the recommended daily dose for 15 consecutive days.

Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Pack sizes:
1 x 50 ml, 1 x 100 ml and 1 x 250 ml (glass vials or polypropylene vials).

Not all pack sizes may be marketed.

Approved: 11 July 2019